Kavita Aggarwal
Chief Tech/Sci/R&D Officer chez VERONA PHARMA PLC
Profil
Kavita Aggarwal is a professional with a current job as Senior Vice President-Medical Affairs at Verona Pharma Plc since 2023.
Prior to this, she worked as VP-Global Commercial Pipeline Strategy at BioCryst Pharmaceuticals, Inc. and as Vice President-Medical Affairs at Dova Pharmaceuticals, Inc. Dr. Aggarwal completed her undergraduate degree at North Carolina State University and her doctorate at the University of North Carolina at Chapel Hill.
Postes actifs de Kavita Aggarwal
| Sociétés | Poste | Début |
|---|---|---|
| VERONA PHARMA PLC | Chief Tech/Sci/R&D Officer | 01/01/2023 |
Anciens postes connus de Kavita Aggarwal
| Sociétés | Poste | Fin |
|---|---|---|
| DOVA PHARMACEUTICALS, INC. | Chief Tech/Sci/R&D Officer | - |
| BIOCRYST PHARMACEUTICALS, INC. | Corporate Officer/Principal | - |
Formation de Kavita Aggarwal
| North Carolina State University | Undergraduate Degree |
| University of North Carolina at Chapel Hill | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
| VERONA PHARMA PLC | Health Technology |
| Entreprise privées | 1 |
|---|---|
Dova Pharmaceuticals, Inc.
 Dova Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Dova Pharmaceuticals, Inc. operates as a clinical-stage pharmaceutical company, which engages in the acquisition, development and commercialization of drug candidates for rare diseases. It focuses on addressing thrombocytopenia, a disorder characterized by a low blood platelet count. Its drug candidate includes avatrombopag, an orally administered thrombopoietin receptor agonist. The company was founded on March 24, 2016 and is headquartered in Durham, NC. | Health Technology |
